Category: Asean

Quantexa to provide category-leading AI-enabled technology, training, and industry expertise to ATII to improve how data is used in the identification and investigation of human trafficking

NEW YORK, Jan. 11, 2024 (GLOBE NEWSWIRE) — Today, Quantexa, a global leader in Decision Intelligence (DI) solutions for the public and private sectors, announced its official corporate sponsorship and Advisory Council membership of the Anti-Human Trafficking Intelligence Initiative (ATII), to mark National Human Trafficking Awareness Day. The ATII is a US-based nonprofit organization whose mission is to fight human trafficking and child exploitation by providing data to advance the prevention, detection, investigation, and reporting mechanisms required to identify potential traffickers and criminal organizations. The International Labor Organization estimates that 50 million¹ people are victims of human trafficking globally, with human trafficking operating as a $150 billion² industry around the world.

Quantexa will provide groundbreaking Decision Intelligence technology, alongside its industry-leading expertise in AI-driven financial crime prevention and detection through training and joint industry engagement. Together, Quantexa and ATII will make pioneering global human trafficking risk data available to more organizations to transform anti-human trafficking efforts and joint initiatives between the private and public sectors.

The Quantexa Decision Intelligence Platform enables organizations to automate data ingestion and matching at unmatched scale and apply graph analytics to visually identify often hard-to-detect activity related to financial crime. Providing access to a wider set of data points specific to human trafficking will enable investigators to take a more robust approach to anti-human trafficking measures. This data, overlaid with persona-based typologies and red flag identification protocols will accelerate the ID of potential human trafficking involvement more quickly, efficiently, and accurately.

“Partnering with Quantexa grants us access to innovative AI technology that will take our mission to fight human trafficking to the next level, transforming our existing processes and providing our partners with improved data to inform investigations faster and more efficiently,” said Aaron Kahler, Founder and CEO of ATII. “Working with Quantexa will put ATII’s data in the hands of more organizations across the public and private sectors, to help detect and eliminate more instances of human trafficking as we work together towards ensuring this type of data is routinely available to investigators.”

“We’re proud to partner with the Anti-Human Trafficking Intelligence Initiative to support the valuable work that the organization is doing to stop human trafficking,” said Clark Frogley, North American Head of Financial Crime Solutions at Quantexa. “Human trafficking is often enabled by illegal financial activity and Quantexa’s deep experience helping organizations to monitor, detect, and investigate financial crimes makes us the ideal partner to support ATII’s mission. This partnership will aid organizations to reinforce their ESG and anti-money laundering (AML) efforts which are critical to stopping human trafficking.”

For more information on global challenges and solutions related to human trafficking, please listen to this podcast featuring Chris Bagnall, Director of Financial Crimes Solutions at Quantexa, Chris Kemp, Director of Enterprise Operations at the ATII and Karim Rajwani, ATII Advisory Council Chairman on Moody’s Talks.

About Quantexa
Quantexa is a global data and analytics software company pioneering Decision Intelligence that empowers organizations to make trusted operational decisions by making data meaningful. Using the latest advancements in big data and AI, Quantexa’s Decision Intelligence platform uncovers hidden risk and new opportunities by providing a contextual, connected view of internal and external data in a single place. It solves major challenges across data management, KYC, customer intelligence, financial crime, risk, fraud, and security, throughout the customer lifecycle.

The Quantexa Decision Intelligence Platform enhances operational performance with over 90% more accuracy and 60 times faster analytical model resolution than traditional approaches. Founded in 2016, Quantexa now has more than 675 employees and thousands of users working with billions of transactions and data points across the world. The company has offices in London, Dublin, Brussels, Malaga, UAE, New York, Boston, Toronto, Sydney, Melbourne, and Tokyo.

For more information, please visit www.quantexa.com or follow us on LinkedIn.

Media Enquiries 
C: Emma Hedges, Executive Vice President, Fight or Flight
E: Quantexa@fightorflight.com

C: Adam Jaffe, SVP of Corporate Marketing
T: +1 609 502 6889
E: adamjaffe@quantexa.com
– or –
RapidResponse@quantexa.com

________________________________

¹ International Labour Organization (ILO), Walk Free and International Organization for Migration (IOM), “Global Estimates of Modern Slavery: Forced Labour and Forced Marriage,” 2022

² International Labour Office (ILO), “Profits and Poverty: The Economics of Forced Labour,” 2014

GlobeNewswire Distribution ID 1000908209

LONDON, Jan. 10, 2024 (GLOBE NEWSWIRE) — Emerging Markets Global Advisory LLP (EMGA), an investment bank specializing in emerging markets, has successfully secured a commitment for USD 30.0 million in senior debt finance for Citizens Development Business Finance PLC (CDB) based in Sri Lanka. EMGA originated, structured, and negotiated this financing arrangement, with the financial support provided by the U.S. International Development Finance Corporation (DFC).

Sajeev Chakkalakal, EMGA’s Head of Investment Banking commented, “Despite the challenges we faced, we are delighted to have delivered again an innovative funding solution for CDB. We believe this marks a significant milestone, in being the first external funding commitment secured for a Sri Lankan NBFI in several years. It will also allow for CDB to continue to support SMEs, including female-owned enterprises, as well as the renewable energy sector in the country.”

Jeremy Dobson, EMGA’s Chief Operating Officer commentated, “CDB’s strong financial standing enabled EMGA to navigate the prevailing macroeconomic headwinds in Sri Lanka to secure the commitment for this funding. This achievement not only underscores EMGA’s expertise in navigating complex financial landscapes, but also highlights the successful collaboration between EMGA, CDB, and DFC in setting a positive precedent for a leading Sri Lankan financial institution to secure external funding in challenging economic climates.”

Maryam Khosharay, DFC’s Deputy Vice President of the Office of Development Credit commented, “We are very glad to continue DFC’s commitment to bolstering investments in Sri Lanka especially those advancing financing for women and green assets in times of economic difficulty and high energy prices.”

Commenting on the transaction, Director Corporate Finance of CDB Roshan Abeygoonewardena opined that CDB has been continually strengthening the bottom of the pyramid as an overarching ethos of its sustainability agenda. “For us women entrepreneurs, especially in the micro and SMEs is where the wheels of the economy turn. Prioritizing women’s empowerment in our business model with access to finance which in turn will spur financial independence and inclusivity will be the panacea in adding fillip to Sri Lanka’s development and economic agenda.”

Emerging Markets Global Advisory LLP (EMGA), based in London and New York helps financial institutions and corporates seeking new debt or equity capital. EMGA’s multi-national team combine the decades of experience necessary to complete transactions within most emerging countries, including Sri Lanka. EMGA continues to expand its geographic reach, solidifying its place as a preeminent, emerging market focused, niche investment bank.

Citizens Development Business Finance PLC (CDB) stands among the five largest non-Bank financial institutions in Sri Lanka and is one of the most innovative financial institutions in the country, with a strong commitment to sustainability, exemplary corporate governance, accountability, and transparency. It is renowned for disrupting the financial services industry with far-reaching technological innovations and cutting-edge financial solutions.

The U.S. International Development Finance Corporation (DFC) is the U.S. Government’s development finance institution. DFC partners with the private sector to finance solutions to the most critical challenges facing the developing world today. We invest across sectors including energy, healthcare, infrastructure, agriculture, and small business and financial services. DFC investments adhere to high standards and respect the environment, human rights, and worker rights.

Contact details
info@emergingmarketsglobaladvisory.com

GlobeNewswire Distribution ID 1000908217

Professor Jerry Mendell and Professor Howard Chang, among other eminent figures, were selected to win the 46th session of the Prize

Riyadh, Saudi Arabia, Jan. 10, 2024 (GLOBE NEWSWIRE) — Professor Jerry Mendell was announced this year’s laureate in King Faisal Prize for Medicine for his groundbreaking contributions to screening, early diagnosis, and treatment of neuromuscular disorders, and Professor Howard Chang was announced this year’s laureate in King Faisal Prize for Science in the field of Biology for his pioneering work in uncovering the significance of long non-coding RNAs in gene regulation and function and his collaborative efforts in advancing genome-wide methodologies to identify DNA regulatory regions. Other laureates’ names were announced to win King Faisal Prize in 2024 for enriching humanity with invaluable achievements and discoveries, and excelling in the fields of Islamic Studies and Serving Islam.

Professor Jerry Mendell’s work lies in the screening, early diagnosis, and treatment of patients with spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD), and limb girdle muscular dystrophies. The Prize’s Medicine topic for 2024 was “Management of Peripheral Disabilities”.

Spinal muscular atrophy (SMA) used to be considered the primary genetic contributor to infant mortality. Around 95% of infants that were diagnosed with SMA, did not survive beyond the age of two. Babies with SMA type 1 are missing a gene called survival motor neuron gene 1 (SMN1) which is vital for their development and its absence prevents them from moving, talking, swallowing, and eventually breathing. Professor Mendell, the Director of Gene Therapy Center at Nationwide Children’s Hospital and Curran Peters Chair in Pediatric Research, used gene-therapy to deliver a healthy gene (SMN1) to patients’ cells. He was the first to demonstrate the safety and efficacy of high doses of AAV-mediated gene transfer therapy for individuals diagnosed with SMA type 1. Adeno-associated viral vectors (AAV) are engineered viruses specifically designed to deliver DNA, and in the context of SMA treatment, they carry the genetic encoding of the healthy SMN gene. His therapeutic approach has garnered worldwide approval, and in 2019 the U.S. Food and Drug Administration granted approval for the first-ever gene therapy treatment for pediatric patients under 2 years of age diagnosed with SMA.

Gene-therapy has also been used by Professor Mendell to correct the genetic mutations for patients suffering from the most common form of muscular dystrophy; Duchenne muscular dystrophy (DMD), a progressive neuromuscular disease. In patients with DMD, genetic mutations prevent cells from making dystrophin; a protein responsible for developing and maintaining healthy muscle tissue. While initial symptoms in DMD patients manifest in skeletal muscles, the condition progresses to impact the heart and respiratory functions. Gene therapy serves to rectify this genetic abnormality, enabling the body to generate dystrophin and impede the ongoing degeneration of muscle tissue. In June 2023, the U.S. Food and Drug Administration approved the first treatment for pediatric patients 4-5 years old with DMD using the novel gene-therapy co-invented by Professor Mendell and Professor Louise Rodino-Klapac; a post-doctoral fellow in Mendell’s lab at the time. A single injection treatment involves administering a micro-dystrophin gene into an adeno-associated virus serotype (AAVrh74), facilitating the delivery of missing or corrected genes to cells.

Professor Mendell has been involved in clinical trials for gene therapy for limb-girdle muscular dystrophy (LGMD) including types 2E, 2B, and 2D. LGMD is an umbrella term that represents several rare types of muscular dystrophy that cause muscle weakness in shoulders, upper arms, hips, and upper legs. It is a chronic condition that affects people of all ages. In one of his studies, Prof. Mendell and his team used a single injection of a low dose of a gene therapy vector to address the primary cellular deficit associated with LGMD2B. The approach repaired the injured muscle fibers, reducing degeneration, and enhancing muscle function.

As author of over 400 papers, Prof. Mendell was elected to the National Academy of Medicine in 2021. He was also recognized by the American Society of Gene and Cell Therapy (ASGCT) with a Translational Science Award in his Name. Science Magazine awarded him the Breakthrough Achievement Award in 2017 for SMA Gene Therapy.

As for this year’s Science Prize in the field of Biology, Professor Howard Chang was announced the laureate, for unveiling the intrinsic role of long non-coding RNAs in gene regulation and function, and for his collaborative endeavors in advancing genome-wide methodologies identifying DNA regulatory regions. Such findings are significantly influencing the realms of molecular biology and genetics, contributing to a deeper understanding of intricate human diseases. His research addresses how large sets of genes are turned on or off together, a key point that helps understand normal development, cancer, and aging.

Professor Howard Chang, a physician-scientist, Professor of Dermatology and Genetics, and Virginia and D.K. Ludwig Professor of Cancer Research at Stanford University, has made significant contributions to the field of RNA medicines. His lab’s work has focused on understanding the roles of long noncoding RNAs (a genetic material found in cells) in biological regulation and their potential therapeutic applications. He discovered long sequences of RNA that, in contrast to the better-known messenger (mRNAs) responsible for protein synthesis, do not encode proteins. Prof. Chang discovered that these sequences play a role in influencing DNA accessibility. They act like a magnet for other RNA molecules and alter mRNA splicing, to affect gene expression, among other duties. Despite not encoding proteins, lncRNAs are crucial for controlling the timing and amount of protein production, impacting the overall function and behavior of cells.

In every human cell, 2 meters of DNA are packed in a 10-micron nucleus, so most of the DNA is highly compacted making most of it inaccessible except for the active DNA elements that the cell is using and reading. Discovering the location of these accessible elements provides insights into the cell’s “software”. Prof. Chang’s lab has pioneered techniques to map the landscape of chromatin; the substance that forms chromosomes and consists of DNA and proteins that structure the genome and control gene expression. One groundbreaking technique innovated by Chang’s lab was the Assay of Transposase Accessible Chromatin, which used an enzyme called Tn5 transposase which copies and pastes DNA. This technique led to a million-fold improvement in the sensitivity and hundred-fold improvement in the speed of mapping regulatory DNA – the epigenome- in human cells.

His work unraveled mechanisms and targets in various human diseases, notably cancer, immunity, and development. His recent investigations into extrachromosomal DNA in cancer revealed key findings. Prof. Chang also established the RNA Medicine Program at Stanford, which works to accelerate the discovery and translation of RNA science into human therapeutics.

Prof. Chang’s honors include the NAS Award for Molecular Biology, Outstanding Investigator Award of the National Cancer Institute, Paul Marks Prize for Cancer Research, Judson Daland Prize of the American Philosophical Society, and the Vilcek Prize for Creative Promise. His work was honored by the journal Cell as a Landmark paper over the last 40 years and by Science as “Insight of the decade”.

In addition to Medicine and Science, King Faisal Prize recognized this year the achievements of an outstanding thinker and scholar in the field of Islamic Studies and exemplary leaders who played a pivotal role in serving Islam, Muslims, and humanity at large.

Professor Wael Hallaq, the Avalon Foundation Professor in the Humanities at Columbia University, was selected to receive the “Islamic Studies” prize in “Islamic Legislations and their Contemporary Applications” for 2024. He has provided an academic reference, parallel to the traditional Orientalist writings, that influenced universities around the world. This was evident in his numerous works that were translated into many languages, and his success in establishing a guideline for the development of Islamic legislation.

As for the Service to Islam Prize, the Japan Muslim Association and Dr. Mohammad Sammak, were announced as co-laureates for this year’s 2024 prize.

King Faisal Prize for Arabic Language & Literature for 2024 on the topic of “Non-Arab Institutions and their Endeavors to Promote Arabic” was withheld due to nominated works not elevating to the criteria of the prize.

King Faisal Prize’s laureates names for 2024 were announced today in Riyadh Saudi Arabia, by HRH Prince Turki Alfaisal and the Prize’s Secretary General Dr. Abdulaziz Alsebail. Since 1979, King Faisal Prize in its 5 different categories has awarded 295 laureates who have made distinguished contributions to different sciences and causes. Each prize laureate is endowed with USD 200 thousand; a 24-carat gold medal weighing 200 grams, and a Certificate inscribed with the Laureate’s name and a summary of their work which qualified them for the prize.

Attachments

• Professor Jerry Mendell
• Professor Howard Chang

Maysa Shawwa
King Faisal Foundation
Maysa.Shawwa@kff.com

GlobeNewswire Distribution ID 9015914

Companies partner to provide patients and sites with easy access to study information in one integrated solution

DURHAM, N.C., Jan. 09, 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced an industry partnership with founding members Veeva Systems Inc., a leading provider of industry cloud solutions for the global life sciences industry, and Advarra, a leading provider of clinical research technology for clinical research investigator sites and sponsors, to deliver an integrated patient- and site-centric solution that streamlines the clinical trial experience.

In an industry faced with complex challenges to clinical trial execution, Fortrea is establishing an alliance of industry partners—beginning with founding members, Veeva and Advarra—to tackle some of these challenges head-on. Many sites are burdened by administrative operations that have multiple, complex technologies with limited interoperability. This impacts their ability to focus on what matters most—the patients—and improving their recruitment and experience participating in clinical studies.

Fortrea, Veeva and Advarra are partnering to offer a seamless, unified technology solution that integrates best-in-class technologies and leverages Fortrea’s process expertise. This will help ease the administrative burden for patients and sites and increase the accessibility of clinical trials for the public.

“We heard from our Site Advisory Board that the multitude of technologies used on a study is one of their greatest challenges,” said Fortrea Chief Operating Officer and President of Clinical Services Mark Morais. “Working with industry-leading partners and founding members, Veeva and Advarra, we’re taking action to remove complexities so we can address the pain points of sites and patients and make a difference. We are leveraging our unique vantage point in the industry that enables us to layer our expertise over the tech and data ecosystems from best-in-class partners—adding to our alliance as we go—to dramatically simplify the experience for patients, sites and sponsors.”

For sites, the partnership is set to deliver:

• a cloud-based, simplified sign-on experience for Fortrea-run studies
• access to study technologies through a single dashboard
• a unified environment with a single repository for study documents and records

For patients, the solution is being designed to offer:

• easy-to-access, step-by-step, visit-by-visit support and education throughout a patient’s trial journey
• a simplified user experience through a single platform
• self-referral functionality to search and find studies in their disease area of interest
• ongoing patient support and education via an online portal or mobile app
• a simplified mobile and web application for consenting and responding to outcome surveys

“Veeva is helping to advance clinical trials with connected applications that reduce the burden of participating for patients, streamline execution for research sites and increase transparency for sponsors,” said Jim Reilly, vice president, Veeva Development Cloud Strategy. “Extending our partnership with Fortrea to deliver Veeva Clinical Platform applications will meet the unique needs of patients, sites and sponsors while significantly improving study data quality and collaboration with sites.”

“Advarra’s mission is to break the silos that impede clinical research, so we are excited to provide our Longboat solution and IRB services as part of this innovative and collaborative partnership aimed at reducing site and patient burden,” said Elisa Cascade, chief product officer at Advarra.  “By leveraging our Longboat solution, Fortrea will deliver a reimagined clinical research experience that will improve both protocol compliance and site and patient engagement throughout the clinical trial process.”

Learn more about how Fortrea is driving healthcare innovation throughout the world at Fortrea.com. For more information on the technology platforms, visit Veeva Clinical Platform and Advarra Longboat.

About Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients in need. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology-enabled trial solutions and post-approval services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team of about 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter) @Fortrea.

Fortrea Contacts:
Fortrea Media: Galen Wilson – 703-298-0802, media@fortrea.com
Fortrea Media: Kate Dillon – 646-818-9115, kdillon@prosek.com

GlobeNewswire Distribution ID 9015283

Potential First-in-Class Novel Molecule with Novel Target In-Licensed from Collaboration with Bayer

SALT LAKE CITY, Jan. 04, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed an agreement with Bayer AG to in-license a new chemical entity that emerged from the companies’ fibrosis research collaboration. The compound represents a novel approach to treating fibrotic diseases with compelling early data suggesting the potential to reverse disease-related fibrotic processes, including immuno-mesenchymal dysfunction.

“Since initiating our research collaboration with Bayer in 2020, we have worked diligently to apply the power of the Recursion OS to identify and advance potential candidates in challenging areas of disease biology,” said Chris Gibson, Ph.D., Co-founder and CEO of Recursion. “We are excited to bring this asset into our internal pipeline and accelerate the compelling science behind this program while our research collaboration with Bayer focuses on precision oncology.”

Recursion applied phenotypic screening of human cells to identify small molecules that reverse the phenotypic features of disease-state fibrocyte cells into those of healthy-state cells. Leveraging the power of Recursion’s Maps of Biology and Chemistry revealed a relationship between small molecule hits and a novel target that could impact fibrotic diseases. The most promising small molecule hits were confirmed as potent inhibitors of this novel target in validation experiments, and lead optimization studies are currently ongoing.

Fibrotic diseases are a significant cause of morbidity and mortality worldwide with high unmet need for patients. One of the biggest challenges in the treatment of fibrotic diseases is the underlying complex biology and the associated difficulty in discovering disease-modifying drug targets. Recursion’s technology is uniquely suited to accelerate discoveries in these and other complex areas of disease biology.

About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology, and chemistry to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal and the San Francisco Bay Area. Learn more at www.Recursion.com, or connect on Twitter and LinkedIn.

Media Contact
Media@Recursion.com

Investor Contact
Investor@Recursion.com

Forward-Looking Statements
This document contains information that includes or is based upon “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding early and late stage discovery, preclinical, and clinical programs; licenses and collaborations; prospective products and their potential future indications and market opportunities; Recursion OS and other technologies; business and financial plans and performance; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.

GlobeNewswire Distribution ID 9012419

WILMINGTON, Del., Jan. 03, 2024 (GLOBE NEWSWIRE) — Enovis Corporation (NYSE: ENOV, “Enovis” or the “Company”) an innovation-driven, medical technology growth company, today announced that it closed the acquisition of LimaCorporate S.p.A. (“Lima”), a privately held global orthopedic leader focused on restoring motion through an innovative portfolio of implant solutions.

Lima strengthens Enovis’ position in the global orthopedic reconstruction market with a complementary portfolio of proven surgical solutions and technologies, which will accelerate global growth and margin expansion. In addition, Lima’s portfolio includes 3D printed Trabecular Titanium implants and a comprehensive revision offering in shoulders, which will further strengthen the Company’s position in the fast-growing extremities market.

“We are excited to welcome Lima’s talented team to Enovis. The combination brings Enovis’ recon segment to $1 billion in revenues and creates a fast-growing innovator in the global orthopedic reconstruction market. This is another great example of how we use strategic acquisitions to accelerate our growth, add great technologies and talent to our company, and drive compounding value for our shareholders,” said Matt Trerotola, Chair, and Chief Executive Officer of Enovis.

About Enovis Corporation
Enovis Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent, and innovation, the Company’s extensive range of products, services, and integrated technologies fuels active lifestyles in orthopedics and beyond. The Company’s shares of common stock are listed in the United States on the New York Stock Exchange under the symbol ENOV. For more information about Enovis, please visit www.enovis.com

Forward-Looking Statements
This press release includes forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements regarding the Company’s plans, objectives, expectations and intentions and other statements that are not historical or current fact. Forward-looking statements are based on the Company’s current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause the Company’s results to differ materially from current expectations include, but are not limited to, risks and uncertainties regarding the Company’s and Lima’s respective businesses, and actual results may differ materially. These risks and uncertainties include, but are not limited to, the effects of the acquisition on the Company’s and Lima’s operations, including on the combined company’s future financial condition and performance, operating results, strategy and plans, including anticipated tax treatment, unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, losses, future prospects, and business and management strategies for the management, expansion and growth of the new combined company’s operations; the potential impact of the consummation of the acquisition on relationships with customers, suppliers and other third parties; and the other factors detailed in the Company’s reports filed with the U.S. Securities and Exchange Commission (the “SEC”), including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption “Risk Factors,” as well as the other risks discussed in the Company’s filings with the SEC. In addition, these statements are based on assumptions that are subject to change. This press release speaks only as of the date hereof. The Company disclaims any duty to update the information herein.

Investor Relations Contact
Kyle Rose
Vice President, Investor Relations
Enovis Corporation
+1-917-734-7450
investorrelations@enovis.com

Media Contact
Katie Sweet
Vice President, Corporate Communications
Enovis Corporation
Katie.sweet@enovis.com

GlobeNewswire Distribution ID 9011517

Foothill Ranch, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) — Sweegen, the global leader in pioneering wellness ingredient and taste modulation technologies, announced a landmark victory in the U.S. Court of Appeals for the Federal Circuit, which has sided with Sweegen and affirmed the invalidation of PureCircle’s patents covering the highly sought-after stevia sweetener Rebaudioside M (Reb M).

Sweegen is the primary producer of non-GMO Reb M originating from the stevia leaf, made with a proprietary clean bioconversion method. This appellate victory further solidifies Sweegen’s technological leadership position in the stevia sweetener industry at large.

Reb M, a highly coveted steviol glycoside molecule, plays a crucial role in the global production of stevia sweeteners. This Federal Circuit decision removes any lingering doubt that Consumer Packaged Goods (CPG) customers may be encumbered by PureCircle’s patents for using Sweegen’s Reb M.

“As one of the staunchest stewards of proprietary technologies in wellness ingredients, Sweegen has actively defended its intellectual property rights while upholding a commitment to respecting the rights of others,” stated Sweegen’s CEO Steven Chen. “Throughout this litigation, we consistently asserted the invalidity of PureCircle’s patents, considering their case against Sweegen as baseless and spurious. This triumph in the U.S. Court of Appeals serves to highlight Sweegen’s dedication to principled innovation and fair competition within the industry.”

In May 2022, Sweegen secured a groundbreaking summary judgment, declaring PureCircle’s asserted patents related to the production of Reb M as invalid. The affirmation today of this judgment by the U.S. Court of Appeals for the Federal Circuit solidifies Sweegen’s position and removes any impediments that PureCircle’s patents may have posed for producers in the United States. Specifically, the federal court’s Opinion confirmed the district court’s decision that certain claims in the patents were found invalid due to a lack of written description. Additionally, it determined that a specific claim in one of the patents is unpatentable under 35 U.S.C. § 101.

“Sweegen’s commitment to innovation, excellence, and fair competition has been reaffirmed through the successful appeal process,” said Chen. “This victory not only strengthens Sweegen’s position in the market but also contributes to the broader landscape of the stevia sweetener industry. Sweegen is positioned to lead the charge in shaping a landscape of limitless possibilities, delivering unparalleled sweetness to consumers and driving positive change on a global scale.”

Sweegen remains committed to driving positive change within the sweetener industry and will continue to invest in research and development to deliver cutting-edge solutions to its global customer base.

In Nov. 2023, Sweegen announced it was addressing the pressing issue of mislabeling within the stevia industry, specifically concerning Reb M stevia sold under intentionally false claims. Through independent testing, the company has determined that certain third-party Reb M products sold to food and beverage companies under label claims of “Reb-M 95%,” “Bioconversion Reb-M 95%,” or “Stevia (Organic) Extract Reb-M 95%” are not made through extraction or bioconversion. Sweegen continues its investigation into the adulterated Reb M.

The U.S. Court of Appeals for the Federal Circuit case is Pure Circle Inc., et al v. Sweegen, et al., case number appeal number 2022-1946.

This Appeal is from the first summary judgment case PureCircle USA Inc., et al. v. Sweegen, Inc., et al., case number 8:18-CV-01679-JVS-JDE, in the United States District Court, Central District of California, Southern Division, Judge James V. Selna. Sweegen was represented at both the US District Court and the Federal Circuit by John Christopher “JC” Rozendaal, Dennies Varughese, Michael E. Joffre, Anna G. Phillips, and Sasha Rao of the law firm Sterne Kessler Goldstein & Fox PLLC.

About Sweegen
Sweegen provides sweet taste solutions for food and beverage manufacturers around the world.

We are on a mission to reduce the sugar and artificial sweeteners in our global diet.  Partnering with customers, we create delicious zero-sugar products that consumers love.  With the best modern sweeteners in our portfolio, such as Bestevia® Rebs B, D, E, I, M, and N, and brazzein, along with our deep knowledge of flavor taste modulators and texturants, Sweegen delivers market-leading solutions that customers want, and consumers prefer. Well. Into the Future.

For more information, please contact info@sweegen.com and visit Sweegen’s website, www.sweegen.com.

Attachment

• The Federal Circuit decision removes any lingering doubt that Consumer Packaged Goods (CPG) customers may be encumbered by PureCircle’s patents for using Sweegen’s Reb M.

Ana Capretz, Head of Public Relations and Communications
Sweegen
+1.949.709.0583
ana.capretz@sweegen.com

GlobeNewswire Distribution ID 9011707

FMF strengthens the Kingdom’s leadership in enabling the Super Region to contribute to the metals industries of the future

RIYADH, Saudi Arabia, Jan. 02, 2024 (GLOBE NEWSWIRE) — The Future Minerals Forum (FMF) announced today that its Ministerial Roundtable, due to be held on 9 January 2024, ahead of the third edition of the Forum, is set to break attendance records. Of the eighty countries so far confirmed to attend, more than forty-five will be sending ministers to take part in discussions with stakeholders in this one meeting, in addition to 20 official international organizations, 30 non-governmental organizations and 13 business associations.

As the highest level gathering on minerals in the world, the Roundtable represents a historic turning point for the global mining and metals sector, the contribution of the Super Region extending from Africa to West and Central Asia, and the Kingdom’s leadership role in this sector and region.

The Ministerial Roundtable is a government-led multi-stakeholder initiative created by Saudi Arabia to enhance international cooperation on producing critical minerals involved in transforming the energy sector. The meeting comes when the mineral sector faces unprecedented challenges driven by the increasing demand for energy transition minerals and metals, where all countries are racing to secure stable supply chains.

Furthermore, the Ministerial Roundtable promotes the importance of collaboration to address this anticipated global challenge.

H.E. Vice-Minister for Mining Affairs, Khalid Al-Mudaifer, highlighted that the number of ministers who had confirmed their attendance at the Roundtable reflects the political and economic weight of the Kingdom and the increasing importance of minerals in recent years, this level of attendance demonstrates that FMF has established itself as a leading global platform for shaping the future of minerals. H.E. stated, “High-level government representation, from countries producing and consuming minerals, means that governments from across the world are now aware of minerals’ importance, as they seek to secure reliable supply chains for them. This is especially relevant to the strategic minerals that are essential to energy transformation programs and projects, and related industries.”

The Roundtable will include discussion of the competition that the metals market is witnessing at international level and how to create room for countries, in the midst of this competition, to reach agreement between themselves.

Media Contact:
Omar Shereen
Omar.shereen@fleishman.com
+966 50 663 0489

GlobeNewswire Distribution ID 1000906717